The late-phase human clinical trials of the Oxford- AstraZeneca vaccine, which is also known as Covishield in India, is giving hopeful results and have not shown any adverse side-effects so far. Covishield is currently in Phase 2 and Phase 3 human clinical trials in the country.
The phase-III human clinical trial began at the Sassoon General Hospital in Pune on September 17. King Edward Memorial (KEM) Hospital in Mumbai on September 23 began the phase II and III trials of the coronavirus vaccine.
Some participants in the trials for the coronavirus vaccine have also received their second doses and have not reported any adverse side-effects.
However, some did develop a fever after the dose of the coronavirus vaccine, but top scientists said that those are mild reactions and should not be worried about.
Some investigators also said that developing a fever is considered a common and mild side-effect of vaccines.
In September, Aztra Zeneca Plc said it has paused a late-stage trial of one of the leading coronavirus vaccine candidates after an unexplained illness in a study participant. After reviews the safety of the vaccine and its procedures, the human trials were resumed.
The Pune-based Serum Institute of India (SII) has partnered with British-Swedish pharma company AstraZeneca for manufacturing the coronavirus vaccine candidate, being developed by the University of Oxford, UK.
